does semaglutide cause thyroid problems can - Does semaglutideaffectthyroidfunction may indirectly promote better thyroid health Does Semaglutide Cause Thyroid Problems? An In-Depth Look at the Evidence

Has anyone gotthyroidcancer from Ozempic reddit The question of does semaglutide cause thyroid problems is a significant concern for individuals considering or currently using this popular medication for weight management or type 2 diabetes. While semaglutide, an incretin mimetic, has shown remarkable efficacy, its potential link to thyroid issues, particularly thyroid cancer, warrants a thorough examination of the available scientific data.Does Ozempic Actually Increase Thyroid Cancer Risk?

Understanding the FDA Warning and Animal Studies

The U.S. Food and Drug Administration (FDA) has issued a boxed warning for medications containing semaglutide, such as Ozempic and Wegovy, citing a potential risk of thyroid tumors, including a type of thyroid cancer called medullary thyroid carcinoma (MTC). This warning is largely based on studies conducted in rodents. In these animal studies, semaglutide and similar GLP-1 receptor agonists (GLP-1RAs) were observed to cause thyroid cancer. Specifically, there's a concern that these drugs can stimulate C-cells in the thyroid, which can lead to the development of these tumors2024年1月4日—Semaglutide's anti-inflammatory propertiesmay indirectly promote better thyroid healthby reducing systemic inflammation. While not a direct .... It is crucial to note that these findings in animals do not definitively equate to the same risk in humans.2024年5月13日—When Ozempic and similar medications stimulate the GLP-1 receptor, it maycauseC-cells to transform. Thiscan lead tomedullarythyroidcancer.

Human Clinical Studies: Reassuring Findings Amidst Concerns

Despite the animal data, the picture in human clinical studies is more nuanced and largely reassuring. Multiple studies and meta-analyses of clinical trials, encompassing thousands of patients, have investigated the association between semaglutide use and thyroid cancerWegovy®is a prescription medicine for adults with obesity, or with overweight and at least one weight-related medicalproblem, along with a reduced-calorie .... The findings from these human trials suggest that semaglutide does not significantly increase the likelihood of developing thyroid tumors or cancer. For instance, some comprehensive analyses involving numerous clinical trials have found no significant association between semaglutide use and an elevated risk of thyroid cancer. Furthermore, a meta-analysis of 45 clinical trials indicated that semaglutide doesn't seem to increase the likelihood of developing any of these thyroid-related issues. Another study looked at patients treated with semaglutide and found the incidence of thyroid cancer was less than 1%, suggesting no significant risk in this observed group.

Semaglutide's Indirect Impact on Thyroid Health

Beyond the direct concern of cancer, there's also discussion about how semaglutide might influence existing thyroid function. Emerging research suggests that semaglutide does not directly alter thyroid hormone production (T3, T4, or TSH). However, some indirect effects have been noted.12602 The Effect of Three-Month Semaglutide Treatment on ... For example, semaglutide treatment significantly alters thyroid hormones and TSH levels in patients with obesity, with some of these alterations being reversible after discontinuation of the medication.2024年1月4日—Semaglutide's anti-inflammatory propertiesmay indirectly promote better thyroid healthby reducing systemic inflammation. While not a direct ... These changes might be more pronounced in individuals with pre-existing hypothyroidism. Notably, some studies suggest that GLP-1 medications, including semaglutide, can reduce TSH levels in hypothyroid patients who lose weight, with semaglutide showing a considerable effect. Additionally, the anti-inflammatory properties of semaglutide may indirectly promote better thyroid health by reducing systemic inflammation, which can be a contributing factor in various health conditions.

Understanding the Risk Factors and Contraindications

While human data suggests a low risk, it's important to acknowledge that the FDA's boxed warning exists. The agency advises against using semaglutide in patients with certain pre-existing conditions. Specifically, GLP-1RAs, including semaglutide, have been contraindicated by the FDA in individuals with a personal or family history of medullary thyroid cancer (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).Risk of Thyroid Cancer Among GLP1-RA Users These conditions predispose individuals to a higher risk of developing MTC, and therefore, the use of semaglutide is not recommended.FAQs

It's also worth considering that increased screening for thyroid cancer in individuals taking Ozempic might lead to a higher rate of diagnosis, even for harmless tumors. This phenomenon, known as increased detection, could skew the perceived risk.

Specific Concerns: Semaglutide and Thyroid Nodules

Another area of inquiry relates to semaglutide and thyroid nodules. While direct causality is not established in humans, the potential for tumor development observed in animal studies raises questions about nodules. Some reports suggest that GLP-1RAs might influence C-cell hyperplasia, which could potentially present as nodules. However, robust human evidence linking semaglutide use directly to an increased incidence of thyroid nodules is yet to be definitively established.Semaglutide: MedlinePlus Drug Information

The Verdict: Weighing the Evidence

In conclusion, regarding whether does semaglutide cause thyroid problems, the current scientific consensus, based on human clinical trials, indicates that the risk of developing serious thyroid issues, including thyroid cancer, is low. The FDA's warning is a precautionary measure stemming from concerning animal studies2024年1月4日—Semaglutide's anti-inflammatory propertiesmay indirectly promote better thyroid healthby reducing systemic inflammation. While not a direct .... However, for individuals with a personal or family history of medullary thyroid cancer or MEN 2, semaglutide is contraindicated due to their increased inherent risk. For the general population, the benefits of semaglutide in managing diabetes and obesity appear to outweigh the perceived risks of thyroid cancer, especially considering the reassuring findings from numerous human studies where the incidence of thyroid cancer has been reported as very low among semaglutide-treated patients.

It is imperative for patients to discuss their medical history thoroughly with their healthcare provider, including any family history of thyroid conditions or cancers, before starting semaglutide. A comprehensive risk-benefit analysis should always guide treatment decisions.作者：P Konopka·2024·被引用次数：1—Semaglutide treatment significantly alters thyroid hormones and TSH levelsin patients with obesity, with some effects reversible post-discontinuation.